Download het volledig rapport (302 p.) - KCE

More documents

Recommendations

Info

KCE reports vol. 6A Prenatale zorg 138 Study Ref Population Intervention Outcomes Results Comments Study type EL al., 2002 pregnancy vs. placebo Very preterm births (n OR 0.86 (95% CI 0.57 to the trials (p = 0.37) Cochrane review or micronutrient = 1578, 2 RCTs) 1.31) supplementation All preterm births (n = OR 0.88 (95% CI 0.68 to ** There were only 3 Most recent update 2002 1577, 2 RCTs) 1.13) maternal deaths Low birth weight (n = OR 0.71 (95% CI 0.40 to 1486, 2 RCTs) 1.28) Very low birth weight OR 0.71 (95% CI 0.40 to (n = 1483, 2 RCTs) 1.28) Postpartum CD4 levels (n = 727, 1 RCT) Weighted mean difference 4.0, 95% CI 51.06 to 43.06 Maternal death (n = OR 0.49 (95% CI 0.04 to 728, 1 RCT)** 5.40) Ricci and 4 436 women between 34 to 38 Caesarean section Adverse effects of Higher rates of fever in Analysis by actual mode RCT 1b Parazzini, [418] weeks pregnancy with delivery vs. vaginal delivery in HIV1 women who gave births of delivery 2000 confirmed HIV-1 diagnosis delivery infected women (i.e., by Caesarean section, but without indication (or fever, wound infection, no significant differences contraindication) for anaesthetic, anaemia, in complication rates caesarean section delivery in other) between women treated various European countries, with zidovudine in including the UK pregnancy and those not treated Cunningham 4 242 from original PACTG Emergence of Detection of resistance Detection of resistance International, OB 3 et al., 2002 [419] (only US and French sites nevirapine resistance mutations prior to mutations prior to multicentre substudy of included) study with 25 mutations at 6 weeks receipt of study drug receipt of study drug: PACTG 316 excluded from final analysis postpartum in women 5/217 women (2.3%) receiving standard Detection of resistance Risk for development of (RCT substudy) antiretroviral treatment mutations at 6 weeks Detection of resistance resistant mutations not postpartum among mutations at 6 weeks correlated with CD4 women who received postpartum among cell counts or HIV-1 the study drug (single women who received the RNA viral load at dose oral 200 mg to study drug: 14/95 (15%, delivery or with type of mother and 2 mg/kg to 95% CI 8 to 23%) antiretroviral therapy
KCE reports vol. 6A Prenatale zorg 139 Study Ref Population Intervention Outcomes infant) Results Comments Study type EL Palumbo et 4 220 HIV infected women and Impact of antiretroviral Detection of resistance 38 women (17.3%) All women received OB 3 al., 2001 [420] n24 of their HIV infected resistance on vertical mutations in mother zidovudine treatment infants from 4 US cities from transmission rates For zidovudine mutation: during pregnancy 1991 to 1997 who received Perinatal transmission 15.8% yes, 15.1% no (NS) zidovudine during pregnancy and maternal presence Phylogenetic and of resistance mutations For nucleotide reverse- genotypic resistance transcriptase inhibitor: 12.5% yes, 16% no (NS) testing 2. i. Rubella Detection of resistance mutation in neonate 2 babies (8.3%) but mutation pattern not identical to mothers What is the rubella susceptibility in women in Belgium? Study Ref Population Intervention Outcomes Results Comments Study Donders et al., 1997 65 1340 eligible women presenting for routine prenatal care at Gasthuisberg University Hospital in Leuven ( Belgium) during 1993 At the beginning of pregnancy a routine screening was offered in one single bloodtube for the following: - Anti-CMV IgG (1043 women were screened) - Anti-rubella IgG (1268 women were screened) - HbsAg (1278 Prevalence of anti-CMV IgG: 16% at age 18 and 50% at age 40 (mean 28.3%) Deficient immunity against rubella: 15/1268 (1.2%) HBsAg carriership 0.23% No HIV infection detected Refusal rate for HIV-screening was 27% EL type CSS 3
Page 1 and 2:
NATIONALE RICHTLIJN PRENATALE ZORG:
Page 3 and 4:
Nationale richtlijn prenatale zorg:
Page 5 and 6:
KCE reports vol. 6A Prenatale zorg
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118: KCE reports vol. 6A Prenatale zorg
Page 167: KCE reports vol. 6A Prenatale zorg
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
This page is left intentionally bla
Page 301:
KCE reports 1. Effectiviteit en kos
show all

Download het volledig rapport (302 p.) - KCE

Create successful ePaper yourself

Delete template?

Save as template?